German pharma company BioNTech is drastically increasing its production capacities for a possible Covid-19 vaccine, the company announced Thursday.
The company is currently developing a candidate vaccine against coronavirus together with US company Pfizer.
BioNTech announced the acquisition of a vaccine plant from the pharma firm Novartis at a press conference.
“In full production operations the production plant will increase BioNTech’s capacity to produce vaccines by about 750 million doses per year or more than 60 million doses per month,” BioNTech said in a press release.
BioNtech reiterated its goal of having its vaccine candidate ready for regulatory approval between the end of October and the beginning of November of this year.
“We have publicly said that we expect our results end of October, beginning of November. If that is the case then we will also hand in our paperwork for approval at the end of October or the beginning of November,” BioNTech CEO Ugur Sahin said at a Thursday press conference.
Sahin said BioNTech and Pfizer plan to deliver some of the first 100 million available doses to the US, once the doses have been approved.
“We will deliver vaccines both to the United States and Europe if the necessary approvals are obtained,” he said.
“We have had multiple talks and are currently preparing paperwork that not only encompasses clinical data, but also data on production quality,” he said.
Sahin added that BioNTech and Pfizer plan to simultaneously seek vaccine approval from regulators in the US and EU.